Shareholders of Corcept Therapeutics Incorporated Should Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights - CORT
MWN-AI** Summary
Shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT) are urged to reach out to Levi & Korsinsky, LLP before April 21, 2026, to discuss their rights in relation to a class action securities lawsuit. This lawsuit seeks to recover losses for investors who may have been impacted by alleged securities fraud occurring between October 31, 2024, and December 30, 2025.
The lawsuit alleges that Corcept made false statements and concealed critical information regarding its drug relacorilant's approval process with the FDA. Specifically, the FDA purportedly expressed concerns about the adequacy of the company's program evaluating relacorilant’s effectiveness in treating hypertension related to hypercortisolism, which was crucial for submitting a New Drug Application (NDA). As a result, Corcept's optimistic statements regarding their interactions with the FDA, and their confidence in obtaining NDA approval, were found to be materially misleading.
Shareholders who experienced financial loss during this time frame may file to serve as lead plaintiff, although participation in any resulting recovery does not necessitate this role. Importantly, there are no out-of-pocket costs for investors who join the class action.
Levi & Korsinsky has built a reputation over two decades for successfully securing compensation for shareholders and has been recognized in the Top 50 Report by ISS Securities Class Action Services for seven consecutive years. Investors who believe they may be affected can contact Joseph E. Levi, Esq. at (212) 363-7500 or via email at jlevi@levikorsinsky.com for further guidance and information on participation.
MWN-AI** Analysis
Shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT) should take proactive steps to assess their rights and potential recourse due to the ongoing class action lawsuit related to the company's alleged securities fraud. The lawsuit, which pertains to events between October 31, 2024, and December 30, 2025, alleges that Corcept misled investors regarding its interactions with the FDA and the viability of its drug, relacorilant, in treating hypertension associated with hypercortisolism. Specifically, the complaint asserts that the company downplayed significant concerns raised by the FDA about the adequacy and design of its clinical study.
This situation presents a crucial opportunity for shareholders who suffered financial losses during the specified period. The deadline to act is April 21, 2026, and contacting Levi & Korsinsky, LLP, a firm known for its strong track record in securities litigation, is an essential step. Shareholders may be eligible for compensation without any out-of-pocket expenses, as the firm operates on a contingency basis.
Investors should carefully consider their options. Engaging with Levi & Korsinsky not only facilitates a potential recovery but also allows investors to gain insights into the legal proceedings that may influence the company’s stock trajectory. The firm's history of successfully securing settlements for similar cases reinforces the importance of submitting a claim or attaching oneself to the case as a lead plaintiff.
In summary, CORT shareholders are strongly encouraged to reach out to Levi & Korsinsky by the April 2026 deadline. Taking prompt action could help ensure that their rights are protected during this critical juncture. Keeping abreast of developments in the lawsuit and company communications will also be vital for informed decision-making moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Shareholders of Corcept Therapeutics Incorporated Should Contact Levi & Korsinsky Before April 21, 2026 to Discuss Your Rights - CORT
PR Newswire
NEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated" or the "Company") (NASDAQ: CORT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Corcept Therapeutics Incorporated investors who were adversely affected by alleged securities fraud between October 31, 2024 and December 30, 2025. Follow the link below to get more information and be contacted by a member of our team:
CORT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: According to the filed complaint, defendants made false statements and/or concealed that: In light of the circumstances in which they were made, not false and misleading. In truth, the FDA had told Corcept that it had concerns about the adequacy of the program assessing relacorilant's effectiveness in treating hypertension in patients with hypercortisolism, including the design of the GRACE study. The FDA had further told Corcept to expect significant issues with the review if Corcept was to submit the NDA. As a result, Defendants' positive statements concerning their interactions with the FDA and their expectations that the relacorilant NDA would be approved, were materially false or misleading.
WHAT'S NEXT? If you suffered a loss in Corcept Therapeutics Incorporated during the relevant time frame, you have until April 21, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE Levi & Korsinsky, LLP
FAQ**
How might the allegations of securities fraud against Corcept Therapeutics Incorporated (CORT) impact the long-term value of shares held by investors participating in the proposed class action?
What specific actions should investors of Corcept Therapeutics Incorporated (CORT) take before the April 21, 20deadline to ensure their rights are protected in this class action lawsuit?
What potential compensation or recovery options could shareholders of Corcept Therapeutics Incorporated (CORT) pursue if the class action lawsuit is successful?
Can you provide details on how the false statements made by Corcept Therapeutics Incorporated (CORT) regarding FDA interactions will be substantiated in court?
**MWN-AI FAQ is based on asking OpenAI questions about Corcept Therapeutics Incorporated (NASDAQ: CORT).
NASDAQ: CORT
CORT Trading
-1.48% G/L:
$38.18 Last:
611,552 Volume:
$38.09 Open:
